Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide vs Carbamazepine as Initial Monotherapy in Epilepsy
NCT01127256Phase 4
Key facts
- Status
- Completed
- Start
- May 2006
- Primary completion
- May 2009
- Countries
- 1
- Sponsor
- Eisai Co., Ltd.
- Modality
- Small Molecules
- Drugs
- zonisamide
- Conditions
- epilepsy
01
Overview
Phase 4, randomised, open-label trial of zonisamide in epilepsy, sponsored by Eisai Co., Ltd. Primary endpoint: Percentage of Participants With Seizure Free Rate at 24 weeks. Started May 2006; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Epilepsy patients over 15 years old with recent seizures and no recent antiepileptic drug use, excluding those with myoclonic/absence seizures or significant organ dysfunction.
04
Endpoints
Primary
Percentage of Participants With Seizure Free Rate
Secondary
Percentage of Participants With Retention Rate
Beyond the preview
Go deeper on NCT01127256.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127256.